MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children - Sorbonne Université Access content directly
Journal Articles Allergy Year : 2016

MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children

Abstract

The objective was to evaluate the efficacy of MP-AzeFlu (Dymista Ò) vs fluticas-one propionate (FP), (both 1 spray/nostril bid), in children with allergic rhinitis (AR). MP-AzeFlu combines azelastine hydrochloride, FP and a novel formulation in a single spray. Children were randomized in a 3 : 1 ratio to MP-AzeFlu or FP in this open-label, 3-month study. Efficacy was assessed in children aged ≥ 6 to <12 years (MP-AzeFlu: n = 264; FP: n = 89), using a 4-point symptom severity rating scale from 0 to 3 (0 = no symptoms; 3 = severe symptoms). Over the 3-month period, MP-AzeFlu-treated children experienced significantly greater symptom relief than FP-treated children (Diff: À0.14; 95% CI: À0.28, À0.01; P = 0.04), noted from the first day (particularly the first 7 days) and sustained for 90 days. More MP-AzeFlu children achieved symptom-free or mild symptom severity status, and did so up to 16 days faster than FP. MP-AzeFlu provides significantly greater, more rapid and clinically relevant symptom relief than FP in children with AR.
Fichier principal
Vignette du fichier
all12903.pdf (258.17 Ko) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

hal-01326275 , version 1 (03-06-2016)

Licence

Attribution - NonCommercial

Identifiers

Cite

W Berger, J Bousquet, A.T. Fox, J Just, A Muraro, et al.. MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy, 2016, ⟨10.1111/all.12903⟩. ⟨hal-01326275⟩
410 View
228 Download

Altmetric

Share

Gmail Facebook X LinkedIn More